Advertisement

Konzeption der kombinierten Chemoimmuntherapie beim oberflächlichen Harnblasenkarzinom

  • U. Engelmann
  • H.-J. Knopf
Conference paper

Zusammenfassung

Interferon wurde als antivirale Substanz 1957 beschrieben. Kurz danach wurde seine Wirksamkeit gegen Krebszellen entdeckt. Diese Eigenschaft konnte aber zunächst nicht weiter geprüft werden, weil Interferon nur in extrem geringen Mengen zur Verfügung stand. Erst die Gentechnologie machte es möglich, größere Mengen humanen Interferons zu produzieren und klinischen Studien zur Verfügung zu stellen. Inzwischen besteht eine Reihe von anerkannten Indikationen für eine Therapie mit Interferon.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ackermann D, Biedermann C, Bailly G, Studer UE (1986) Behandlung oberflächlicher Blasentumoren mit rIFN-alpha A Instillationen (Referon A): Eine Phase I/II Studie. Verhandlungsbericht der Deutschen Gesellschaft für Urologie, 37. Tagung. Thieme, Stuttgart, S 211–213Google Scholar
  2. Bahnson RB, Ratcliff TL (1990) In vitro und in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2) J Urol 144: 172–175PubMedGoogle Scholar
  3. Bonnern EM (1987) Alpha interferon: a look into the future. Invest New Drugs 5: 65–75Google Scholar
  4. Borden EC, Sidkey YA, Erturk E (1990) Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine. Cancer Res 50: 1071–1074PubMedGoogle Scholar
  5. Borden EC, Sidkey YA, Groveman DS, Bryan GT (1985) Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophsophamide. Cancer Res 45: 45–50PubMedCrossRefGoogle Scholar
  6. Brouty-Boyce D, Mogensen KE, Gresser I (1985) Effects of long-term treatment of human carcinoma cells with interferon alpha. Eur J Cancer Clin Oncol 21: 507–514CrossRefGoogle Scholar
  7. Christopherson IS, Jordal R, Osther K, Lindenberg J, Pederson PH, Berg K (1978) Interferon therapy in neoplastic disease. A prelaminary report. Acta Med Scand 204: 471–476CrossRefGoogle Scholar
  8. Donovan MG, Grainger R, Hegarty JH, Butler MR, Fitzpatrick JM (1987) A prospective, randomized study of intravesical BCG and interferon in superficial bladder cancer. Presented as a poster at the 4th European Conference on Clinical Oncology and Cancer Nursing, Madrid (1987)Google Scholar
  9. Frangos DN, Killion JJ, Fan D, Fishbeck R, Eschenbach AC von, Fidler IJ (1990) The development of liposomes containing interferon alpha for the intravesical therapy of human bladder cancer. J Urol 143: 1252–1256PubMedGoogle Scholar
  10. Glashan RW (1990) A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder. J Urol 144: 658–661PubMedGoogle Scholar
  11. Grups JW, Frohmüller HGW (1988) Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro. Urol Int 43: 265–268PubMedCrossRefGoogle Scholar
  12. Graps JW, Frohmüller HGW, Ackerman R (1985) Immunological findings in patients with superficial bladder cancer during human alpha-2 interferon treatment. Urol Int 40: 301–306CrossRefGoogle Scholar
  13. Höltl W, Hasun R, Albrecht W, Marberger M (1987) Topical interferon alpha-2 b low dose vs high dose ethoglucid for preventing recurrent superficial bladder cancer. Presented as a poster at the 4th European Conference on Clinical Oncology and Cancer Nursing, Madrid (1987)Google Scholar
  14. Hubell HR, Kvalnes-Krick K, Carter WA, Strayer DR (1985) Antiproliferative and immunomodulatory actions of beta-Interferon and double-stranded RNA, individually and in combination of human bladder tumor xenografts in nude mice. Cancer Res 45: 2481–2486Google Scholar
  15. Ikic D, Maricic Z, Oresic V et al. (1981) Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer and melanoma. Lancet I: 1022–1024Google Scholar
  16. Jakse G, Marth C, Zechner J, Daxenbichler G (1988) Antiproliferative effect of Hu-interferon-gamma in 674V and J82 bladder carcinoma cell lines. Urol Res 16: 403–405PubMedCrossRefGoogle Scholar
  17. Khaled HM, Attia MM, Nanawai AR (1990) Evaluation of in vitro effects of recombinant human alpha 2 interferon on bilharzial urinary bladder cancer cells. Tumori 76: 582–584PubMedGoogle Scholar
  18. Kemeny N,Yagoda A,WangY, Field K,Wroblewski H,Whitmore W (1981) Randomized trial of standard therapy with or without poly I: C in patients with superficial bladder. Cancer 48: 2154–2157PubMedCrossRefGoogle Scholar
  19. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, Aravantinos G, Dimopoulos MA (1990) Intravesical interferon alpha-2b administration in the treatment of superficial bladder tumors. Eur Urol 18: 201–203PubMedGoogle Scholar
  20. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ (1991) Fluoruracil and recombination human interferon alpha-2 a in the treatment of metastatic chemotherapyrefractory urothelial tumors. J Natl Cancer Inst 83: 285–288PubMedCrossRefGoogle Scholar
  21. MoritaT (1984) Treatment of bladder cancer by topical injection HLB1. Jpn J Clin Urol 38: 875–878Google Scholar
  22. Nijima T (1989) Intravesival treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT- Beta Research Group. Cancer Immunol Immunother 30: 81–85CrossRefGoogle Scholar
  23. Oliver RTD, Waxman JH, Kwok H (1986) Alpha lymphoblastoid interferon for noninvasive bladder cancer. Br J Cancer 53: 432Google Scholar
  24. Sarosdy MF, Kierum CA (1989) Combination immunotherapy of murine transitional cell cancer using BCG and an interferon binding pyrimidinone. J Urol 142: 1376–1379PubMedGoogle Scholar
  25. Schmitz-Dräger BJ, Ebert T, Ackermann R (1986) Intravesical treatment of superficial bladder carcinoma with interferons. World J Urol 3: 218–223CrossRefGoogle Scholar
  26. Scorticatti CH, de la Pena NC, Bellora OG, Mariotto RA, Casabe AR, Comolli R (1982) Systemic IFN-alpha treatment of multiple papilloma grade I or II patients: pilot study. J Interferon Res 2: 339–343PubMedCrossRefGoogle Scholar
  27. Shortliffe LC, Freiha FS, Hannigan JF et al. (1984) Intravesical interferon therapy for carcinoma — in situ and transitional cell carcinoma of the bladder. J Urol 133: 171A-271Google Scholar
  28. Torti FM, Shortliffe LD, Williams RD et al. (1988) Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study. J Clin Oncol 6: 476–483PubMedGoogle Scholar
  29. Williams RD (1988) Intravesical interferon alpha in the treatment of superficial bladder cancer. Semin Oncol 15 [Suppl. 5]: 10–13PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • U. Engelmann
  • H.-J. Knopf

There are no affiliations available

Personalised recommendations